HLA-C and cancer: Loss of MHC molecules may lead to immune-escape which may entail the failure of clinically relevant immune surveillance, loss of individual MHC class I loci in cancer lesions prohibits targeted therapy using PCV, since the identification of allelic losses limits naturally the choice of peptides to be used in a PCV.